Pityriasis Rosea Eruption Following the Administration of Oxford-AstraZeneca Vaccine

TL;DR

A 37-year-old woman developed pityriasis rosea after receiving the Oxford-AstraZeneca vaccine, a rare skin condition not commonly reported with this vaccine.

Contribution

This case report is unique in documenting pityriasis rosea following the Oxford-AstraZeneca vaccine, not previously widely associated with this condition.

Findings

A 37-year-old woman developed clinical and histological evidence of pityriasis rosea after the second dose of the Oxford-AstraZeneca vaccine.

The patient had previously received the Pfizer-BioNTech vaccine without similar skin reactions.

The patient received a booster dose of the Pfizer-BioNTech vaccine without any adverse effects.

Abstract

The coronavirus disease 2019 (COVID-19) infection has led to accelerated development and utilization of vaccines to prevent its implications on health. One of these vaccines is a vector-based, Oxford-AstraZeneca Vaccine (AZD1222). Frequently reported side effects are related to host-immune response. While dermatologic manifestation is peculiar in nature and denotes a serious eruption that might defer future vaccination. Herein, we present a case of a medically free 37-year-old female who developed clinical and histological evidence of pityriasis rosea (PR) after administration of a second-dose vaccination of AZD1222. The first dose of vaccination was administered as Pfizer BioNTech COVID-19 mRNA (BNT162b2) vaccine. This case is unique in nature as this patient developed AZD1222-induced PR, while some reports in the literature have linked PR to the BNT162b2 vaccine. This patient continued to receive a booster vaccination with BNT162b2 with no reportable side effects.

Figures